Sorrento's mRNA COVID-19 Vaccine Shows Efficacy In Preclinical Study

Sorrento Therapeutics Inc SRNE has announced preclinical results for its mRNA-based COVID-19 vaccine against SARS-CoV-2.
STI-mRNA includes a proprietary designer Spike-encoding mRNAs to elicit cellular and humoral immunity against the early virus strain and emerging variants of concern.
The MuVaxx lymphatic drug delivery device is designed to deliver the vaccine into the epidermis at lower doses than intramuscular administration.
Intramuscular (IM) STI-mRNA (10µg) compared to the IM LNP-mRNA (10µg) showed a 400% improvement in cellular immunity as measured by cytokine production of spike-specific CD8 T cells.
The elevated cellular immune response was also observed at 1/10th of the STI-mRNA dose using the MuVaxx lymphatic drug delivery device.
STI-mRNA (1/10th dose delivered with MuVaxx) also demonstrated similar humoral immunity (antibodies) as compared to the IM LNP-mRNA reference (10µg) and IM STI-mRNA (10µg).
Related: Sorrento In-Licenses COVID-19 Targeted MPro Inhibitors.
Price Action: SRNE shares are down 2.41% at $9.10 during the market session on the last check Thursday.
Photo by Spencer Davis from Pixabay